How parallel workstreams and interdepartmental coordination accelerated startup for an add-on neurology site
Joining a clinical trial already in progress presents a different kind of startup challenge. With recruitment underway and study timelines already moving, an add-on site may have significantly less time to complete the regulatory, contractual, operational, and patient-readiness work required before enrollment can begin.
For one neurology clinical trial, Profound Research was selected as an add-on site on April 24, 2025, with the duration of screening still to be determined. Despite the limited runway, the site was expected to be fully operational and enrollment-ready by mid-May.
Profound prioritized the study across departments and moved multiple startup activities forward in parallel.
On May 13, the site received Greenlight and was ready to enroll—14 business days after site selection.
The Challenge: Joining a Study Already in Progress
When Profound was selected on April 24, the study was already underway.
As an add-on site, the team needed to complete the startup process quickly enough to contribute to enrollment within the remaining study timeline. With the duration of screening still to be determined and a target of mid-May for enrollment readiness, there was little room for unnecessary delay.
The challenge required more than simply moving individual startup tasks faster. Regulatory approval, contracting, site initiation, and patient readiness all needed to advance within the same compressed timeframe.
The Solution: Parallel Workstreams Across Departments
Profound prioritized the study across departments rather than approaching startup as a strictly sequential process.
The team combined the Pre-Study Visit (PSV) and Site Initiation Visit (SIV) into a single visit on May 1, reducing the time required to complete these startup activities.
The IRB submission followed on May 2, while patient pre-screening and enrollment-readiness activities were already underway. IRB approval was secured on May 7, five days after submission.
At the same time, contracting moved forward. The Clinical Trial Agreement (CTA) and budget were finalized within nine business days.
By advancing regulatory, contracting, site initiation, and patient-readiness activities in parallel, the team compressed the overall startup timeline without waiting for one workstream to finish before progressing another.
The Outcome: Enrollment-Ready by May 13
On May 13, Profound received Greenlight and was ready to enroll.
From site selection to enrollment readiness, the process took 14 business days, with key startup activities completed along the way:
Key Study Achievements:
- April 24: Site selected
- May 1: PSV and SIV conducted in a single visit
- May 2: IRB submitted; patient pre-screening and readiness underway
- May 7: IRB approval secured; CTA and budget finalized
- May 13: Greenlight received; site ready to enroll
The accelerated startup reflected close interdepartmental coordination across the activities required to move the site from selection to enrollment readiness within a limited window.
What This Means for Sponsors
Adding a site to a study already in progress creates a fundamental timing challenge: every additional day spent on startup reduces the site’s opportunity to contribute to recruitment.
This case demonstrates how parallel execution can help address that challenge.
Rather than treating regulatory, contracting, site initiation, and patient readiness as isolated sequential steps, Profound advanced them concurrently. Combining the PSV and SIV further reduced the startup timeline, while pre-screening before Greenlight helped prepare the site for enrollment once activation requirements were complete.
For sponsors, this approach can help an add-on site move from selection to meaningful enrollment readiness quickly—even when the study is already underway and the remaining recruitment window is uncertain.
Looking Ahead
Accelerated startup depends on more than speed. It requires coordination across teams, clear priorities, and the ability to advance multiple workstreams without sacrificing the accuracy required for study activation.
In this neurology trial, Profound moved from site selection on April 24 to Greenlight on May 13—14 business days—while securing IRB approval, finalizing the CTA and budget, completing the PSV and SIV, and beginning patient pre-screening and readiness activities.
The result demonstrates how coordinated, parallel execution can help sponsors bring additional sites online quickly and position them to contribute to enrollment when time matters most.